STERIS plc (NYSE:STE) Expected to Post Q3 2026 Earnings of $2.60 Per Share

STERIS plc (NYSE:STE) – Investment analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for shares of STERIS in a report issued on Tuesday, August 27th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $2.60 for the quarter, up from their previous forecast of $2.32. The consensus estimate for STERIS’s current full-year earnings is $9.17 per share. Zacks Research also issued estimates for STERIS’s Q1 2027 earnings at $2.45 EPS and FY2027 earnings at $10.53 EPS.

A number of other equities analysts have also commented on STE. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Stephens restated an “overweight” rating and issued a $260.00 price target on shares of STERIS in a research report on Wednesday, August 7th. StockNews.com raised shares of STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. JMP Securities reissued a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a report on Wednesday, August 7th. Finally, Piper Sandler restated a “neutral” rating and issued a $225.00 target price (up from $220.00) on shares of STERIS in a research report on Friday, May 10th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $243.60.

STERIS Stock Up 1.4 %

NYSE STE opened at $241.10 on Friday. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. The company has a market cap of $23.78 billion, a price-to-earnings ratio of 63.12 and a beta of 0.83. The company has a 50 day moving average of $228.94 and a 200-day moving average of $224.50. STERIS has a 1-year low of $195.47 and a 1-year high of $243.37.

STERIS (NYSE:STE) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. The business had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. STERIS’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period last year, the firm earned $2.00 earnings per share.

Institutional Trading of STERIS

A number of institutional investors and hedge funds have recently bought and sold shares of STE. Norges Bank acquired a new position in STERIS during the 4th quarter worth about $220,954,000. Massachusetts Financial Services Co. MA lifted its stake in shares of STERIS by 13.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock worth $1,414,453,000 after acquiring an additional 778,613 shares during the period. APG Asset Management US Inc. acquired a new position in shares of STERIS in the fourth quarter worth approximately $74,963,000. Sustainable Growth Advisers LP boosted its holdings in STERIS by 23.5% in the first quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after acquiring an additional 282,387 shares during the last quarter. Finally, Impax Asset Management Group plc increased its position in STERIS by 29.7% during the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock valued at $251,663,000 after purchasing an additional 263,383 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the sale, the director now owns 582 shares in the company, valued at approximately $139,493.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.14% of the company’s stock.

STERIS Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, September 5th will be given a $0.57 dividend. The ex-dividend date is Thursday, September 5th. This represents a $2.28 dividend on an annualized basis and a yield of 0.95%. This is a positive change from STERIS’s previous quarterly dividend of $0.52. STERIS’s dividend payout ratio (DPR) is currently 54.45%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.